Myriad Genetics | MYGN - Equity Capital And Reserves


Myriad Genetics reported $337.4M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Agilent USD 7.12B 214M Mar/2026
Becton, Dickinson and Co. USD 24.13B 1.15B Mar/2026
Bio-Rad Laboratories USD 6.85B 602.3M Mar/2026
Bruker USD 2.46B 35.9M Dec/2025
Danaher USD 52.95B 415M Mar/2026
Illumina USD 2.68B 47M Mar/2026
J&J USD 81.19B 358M Mar/2026
Mettler Toledo International USD -41.88M 18.25M Mar/2026
Myriad Genetics USD 337.4M 30.6M Mar/2026
OraSure Technologies USD 313.32M 27.5M Mar/2026
Pacific Biosciences Of California USD 2.37M 2.98M Mar/2026
Quest Diagnostics USD 7.37B 196M Mar/2026
Quidel USD 1.85B 69.1M Mar/2026
Repligen USD 2.11B 666K Mar/2026
Revvity USD 7.25B 125.54M Dec/2025
Standard Biotools USD 561.12M 136.83M Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Veracyte USD 1.34B 34.83M Mar/2026
Waters USD 2.56B 230.55M Dec/2025